Publications by authors named "Julia Rotow"

13Publications

Turnaround Time of Plasma Next-Generation Sequencing in Thoracic Oncology Patients: A Quality Improvement Analysis.

Authors:
Yi Lee Evan W Clark Marina S D Milan Christine Champagne Kesi S Michael Mark M Awad David A Barbie Michael L Cheng Kenneth L Kehl J Paul Marcoux Michael S Rabin Julia K Rotow Jacob M Sands Pasi A Jänne Geoffrey R Oxnard

JCO Precis Oncol 2020 21;4. Epub 2020 Sep 21.

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA.

View Article and Find Full Text PDF
September 2020

Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing.

Authors:
Ashley Maynard Caroline E McCoach Julia K Rotow Lincoln Harris Franziska Haderk D Lucas Kerr Elizabeth A Yu Erin L Schenk Weilun Tan Alexander Zee Michelle Tan Philippe Gui Tasha Lea Wei Wu Anatoly Urisman Kirk Jones Rene Sit Pallav K Kolli Eric Seeley Yaron Gesthalter Daniel D Le Kevin A Yamauchi David M Naeger Sourav Bandyopadhyay Khyati Shah Lauren Cech Nicholas J Thomas Anshal Gupta Mayra Gonzalez Hien Do Lisa Tan Bianca Bacaltos Rafael Gomez-Sjoberg Matthew Gubens Thierry Jahan Johannes R Kratz David Jablons Norma Neff Robert C Doebele Jonathan Weissman Collin M Blakely Spyros Darmanis Trever G Bivona

Cell 2020 Sep 20;182(5):1232-1251.e22. Epub 2020 Aug 20.

Department of Medicine, University of California, San Francisco, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address:

View Article and Find Full Text PDF
September 2020

What's Old Is New Again: Revisiting Up-Front Chemotherapy in -Mutated Non-Small-Cell Lung Cancer.

Authors:
Julia K Rotow Pasi A Jänne

J Clin Oncol 2020 01 27;38(2):107-110. Epub 2019 Nov 27.

Dana-Farber Cancer Institute, Boston, MA.

View Article and Find Full Text PDF
January 2020

Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.

Authors:
Julia K Rotow Philippe Gui Wei Wu Victoria M Raymond Richard B Lanman Frederic J Kaye Nir Peled Ferran Fece de la Cruz Brandon Nadres Ryan B Corcoran Iwei Yeh Boris C Bastian Petr Starostik Kimberly Newsom Victor R Olivas Alexander M Wolff James S Fraser Eric A Collisson Caroline E McCoach D Ross Camidge Jose Pacheco Lyudmila Bazhenova Tianhong Li Trever G Bivona Collin M Blakely

Clin Cancer Res 2020 01 23;26(2):439-449. Epub 2019 Sep 23.

Department of Medicine, University of California, San Francisco, California.

View Article and Find Full Text PDF
January 2020

A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600 mutant advanced melanoma.

Authors:
Alain Patrick Algazi Julia Rotow Christian Posch Susana Ortiz-Urda Alyson Pelayo Pamela N Munster Adil Daud

Pigment Cell Melanoma Res 2019 07 13;32(4):603-606. Epub 2019 Apr 13.

UCSF Hematology and Oncology, San Francisco, California.

View Article and Find Full Text PDF
July 2019

Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation.

Authors:
Julia K Rotow Gavitt A Woodard Anatoly Urisman Caroline E McCoach Trever G Bivona Brett M Elicker David M Jablons Collin M Blakely

Clin Lung Cancer 2019 03 20;20(2):e137-e141. Epub 2018 Nov 20.

Department of Medicine, University of California, San Francisco, San Francisco, CA; Hellen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA. Electronic address:

View Article and Find Full Text PDF
March 2019

Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins.

Authors:
Dana S Neel David V Allegakoen Victor Olivas Manasi K Mayekar Golzar Hemmati Nilanjana Chatterjee Collin M Blakely Caroline E McCoach Julia K Rotow Anh Le Niki Karachaliou Rafael Rosell Jonathan W Riess Robert Nichols Robert C Doebele Trever G Bivona

Cancer Res 2019 02 11;79(3):546-556. Epub 2018 Dec 11.

Department of Medicine, University of California at San Francisco, San Francisco, California.

View Article and Find Full Text PDF
February 2019

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.

Authors:
Khyati N Shah Roma Bhatt Julia Rotow Julia Rohrberg Victor Olivas Victoria E Wang Golzar Hemmati Maria M Martins Ashley Maynard Jonathan Kuhn Jacqueline Galeas Hayley J Donnella Swati Kaushik Angel Ku Sophie Dumont Gregor Krings Henry J Haringsma Liliane Robillard Andrew D Simmons Thomas C Harding Frank McCormick Andrei Goga Collin M Blakely Trever G Bivona Sourav Bandyopadhyay

Nat Med 2019 01 26;25(1):111-118. Epub 2018 Nov 26.

Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA.

View Article and Find Full Text PDF
January 2019

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.

Authors:
Collin M Blakely Thomas B K Watkins Wei Wu Beatrice Gini Jacob J Chabon Caroline E McCoach Nicholas McGranahan Gareth A Wilson Nicolai J Birkbak Victor R Olivas Julia Rotow Ashley Maynard Victoria Wang Matthew A Gubens Kimberly C Banks Richard B Lanman Aleah F Caulin John St John Anibal R Cordero Petros Giannikopoulos Andrew D Simmons Philip C Mack David R Gandara Hatim Husain Robert C Doebele Jonathan W Riess Maximilian Diehn Charles Swanton Trever G Bivona

Nat Genet 2017 Dec 6;49(12):1693-1704. Epub 2017 Nov 6.

Department of Medicine, University of California, San Francisco, San Francisco, California, USA.

View Article and Find Full Text PDF
December 2017

Understanding and targeting resistance mechanisms in NSCLC.

Authors:
Julia Rotow Trever G Bivona

Nat Rev Cancer 2017 10;17(11):637-658

Department of Medicine, Division of Hematology and Oncology, University of California San Francisco, 505 Parnassus Avenue, Box 1270, San Francisco, California 94143, USA.

View Article and Find Full Text PDF
October 2017

Pharmacokinetics, clinical indications, and resistance mechanisms in molecular targeted therapies in cancer.

Authors:
Benjamin Izar Julia Rotow Justin Gainor Jeffrey Clark Bruce Chabner

Pharmacol Rev 2013 3;65(4):1351-95. Epub 2013 Oct 3.

10 North Grove Street, LRH 214, Boston, MA, 02114.

View Article and Find Full Text PDF
February 2014

Vaccines as monotherapy and in combination therapy for prostate cancer.

Authors:
Julia Rotow Sofia R Gameiro Ravi A Madan James L Gulley Jeffrey Schlom James W Hodge

Clin Transl Sci 2010 Jun;3(3):116-22

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

View Article and Find Full Text PDF
June 2010

RBM5/H37 tumor suppressor, located at the lung cancer hot spot 3p21.3, alters expression of genes involved in metastasis.

Authors:
Juliana J Oh Eileen O Taschereau Ashley K Koegel Charles L Ginther Julia K Rotow Khadijeh Z Isfahani Dennis J Slamon

Lung Cancer 2010 Dec 24;70(3):253-62. Epub 2010 Mar 24.

Division of Hematology/Oncology, University of California at Los Angeles School of Medicine, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA.

View Article and Find Full Text PDF
December 2010